Tech

October 12, 2012

NASA signs agreement to develop nasal spray for motion sickness

NASA’s Johnson Space Center in Houston and Epiomed Therapeutics Inc. of Irvine, Calif., have signed an agreement to develop and commercialize a NASA-crafted, fast-acting nasal spray to fight motion sickness.

Under the Space Act Agreement, Epiomed will formulate the drug, called intranasal scopolamine, or INSCOP. Astronauts often experience motion sickness in space. As a result, NASA has conducted extensive research into the causes and treatments for the condition. Scopolamine is effective and can be administered as a tablet or injected. With

precise dosage, the NASA spray formulation has been shown to work faster and more reliably than the oral form.

“NASA and Epiomed will work closely together on further development of INSCOP to optimize therapeutic efficiency for both acute and chronic treatment of motion sickness which can be used by NASA, the Department of Defense and world travelers on land, in the air and on the seas,” said Lakshmi Putcha, developer of the innovative treatment strategy at Johnson.

A gel formulation of INSCOP was developed and tested under a Space Act Agreement between Johnson and the Naval Aerospace Medical Research Laboratory in Pensacola, Fla. Results from that trial were published in the journal Aviation, Space and Environmental Medicine in April 2010 that suggest INSCOP is a fast-acting and reliable way to prevent and treat motion sickness.

The U.S. Navy is working on an agreement with Epiomed to test the nasal spray. NASA and Epiomed will collaborate on clinical trials related to the Federal Drug Administration requirements. NASA is transferring sponsorship of future clinical trials and FDA approvals to Epiomed, which will supply the product for use by NASA and others.

 




All of this week's top headlines to your email every Friday.


 
 

 

Headlines July 27, 2015

News: U.S.-Turkey deal aims to create de facto ‘safe zone’ in northwest Syria – Turkey and the United States have agreed on the outlines of a de facto “safe zone” along the Turkey-Syria border under the terms of a deal that is expected to significantly increase the scope and pace of the U.S.-led air war against...
 
 

News Briefs July 27, 2015

Putin OKs maritime code calling for strong Atlantic presence Russian President Vladimir Putin has approved a new version of the country’s maritime doctrine that calls for maintaining a strong Russian presence in the Atlantic Ocean amid concerns about NATO expansion. The doctrine, which covers naval, merchant marine and scientific maritime issues, also adds the Antarctic...
 
 
Army photograph by SFC Walter E. van Ochten

U.S., Ukraine, Romania, Bulgaria train together at Rapid Trident 2015

Army photograph by SFC Walter E. van Ochten U.S. soldiers, of the 3rd Platoon, 615th Military Police Company, 709th Military Police Battalion, react as they conduct reacting to contact training as part of their situational trai...
 

 
nasa-astronaut

Astronaut Stephen Frick retires from NASA

Astronaut Stephen Frick has retired from NASA to accept a position in the private sector. Frick, who flew as both a shuttle pilot and commander, left the Agency July 13. Steve has been a great asset to the astronaut office and ...
 
 
Army photograph by Sgt. Juana M. Nesbitt

Estonian, US forces receive new jump wings

Army photograph by Sgt. Juana M. Nesbitt Pvt. Kalmer Simohov, of Parnu, a volunteer with the Estonian Defense League, receives his U.S. Army Airborne wings following the joint airborne operations exercise at a drop zone in Nurm...
 
 

Lockheed Martin, StemRad studying first-responder radiation shield for potential deep-space application

StemRad, Ltd. and Lockheed Martin have initiated a joint research and development effort to determine if StemRad’s radiation shielding technology ñ originally designed for first-responders ñ could help to keep astronauts safe on deep-space exploration missions. This collaboration is part of Lockheed Martin’s ongoing effort to establish international partnerships for human explorat...
 




0 Comments


Be the first to comment!


Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>